Vera Therapeutics (VERA) Projected to Announce Quarterly Earnings on Tuesday

Vera Therapeutics (NASDAQ:VERA) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Vera Therapeutics to announce earnings of ($1.58) per share and revenue of $1.2810 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 12:30 PM ET.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the prior year, the company posted ($0.81) earnings per share. On average, analysts expect Vera Therapeutics to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vera Therapeutics Stock Down 2.9%

VERA stock opened at $32.10 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The stock has a market capitalization of $2.30 billion, a P/E ratio of -5.79 and a beta of 0.92. Vera Therapeutics has a fifty-two week low of $19.07 and a fifty-two week high of $56.05. The business has a 50-day moving average of $36.91 and a 200-day moving average of $39.63.

Analyst Ratings Changes

Several equities research analysts have commented on VERA shares. HC Wainwright boosted their target price on Vera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a research note on Wednesday, July 8th. Wedbush lifted their price objective on shares of Vera Therapeutics from $35.00 to $43.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, Bank of America increased their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $84.58.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,250 shares of company stock worth $3,337,770 over the last ninety days. Corporate insiders own 15.90% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Several large investors have recently made changes to their positions in VERA. Massar Capital Management LP acquired a new position in Vera Therapeutics during the second quarter worth $377,000. Jain Global LLC acquired a new stake in Vera Therapeutics in the fourth quarter valued at $361,000. Commonwealth Equity Services LLC bought a new position in shares of Vera Therapeutics in the 4th quarter valued at about $311,000. Virtu Financial LLC bought a new position in shares of Vera Therapeutics in the 4th quarter valued at about $297,000. Finally, Virtus Investment Advisers LLC increased its stake in shares of Vera Therapeutics by 5.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after purchasing an additional 290 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.